Skip to main content
SpringerLink
Log in

A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

There is general agreement that most chemotherapy agents achieve only relatively low concentrations in the normal central nervous system, that the blood-brain barrier is variably disrupted in malignant brain tumors, and that the concentration of chemotherapy drugs in the brain adjacent to tumor is intermediate between concentrations achieved in brain tumors vs normal brain. However, there is substantial controversy regarding the role of the blood-brain barrier in resistance to chemotherapy of intracerebral tumors. Many chemotherapy agents achieve concentrations in brain tumors that are comparable to those in extracerebral tumors, and drugs that cross the intact blood-brain barrier only poorly may be active against intracerebral tumors. Furthermore, the hypothesis that the brain is a pharmacological sanctuary where metastases may grow while tumor is responding in other parts of the body may be flawed: there are only 2 or 3 types of malignancies (out of all those that are sensitive to chemotherapy) in which the risk of isolated central nervous system relapse is moderately high, and even in these 2 or 3, effective central nervous system prophylaxis has minimal or no impact on overall survival. Furthermore, drugs that cross the BBB do not appear to be more effective than other drugs at reducing the risk of brain metastases, and brain metastases at the time of diagnosis do not necessarily convey a worse prognosis than metastases to various other sites.

While average drug concentrations in brain adjacent to tumor are lower than those within brain tumors, very small numbers of tumor cells may be capable of inducing local leakiness in blood vessels, and there is little information on drug concentrations achieved in individual tumor cells within the brain adjacent to tumor. Furthermore, any limitation of uptake of drugs into brain tumors could be at least partially due to increased tissue pressure within tumors rather than being due to blood-brain barrier phenomena. This distinction could be important, since strategies that one might use to increase drug delivery to brain tumors might differ depending on whether the reduced delivery were due to barrier phenomena vs blood flow phenomena.

The role of the blood-brain barrier in resistance of intracerebral tumors to chemotherapy remains unclear: while it may well play some role (and perhaps even a major one), self-fulfilling prophecies and unintentional bias in data selection and interpretation may have previously made it appear more important than it actually is. The feeling by many investigators that the blood-brain barrier is a major factor in brain tumor resistance to chemotherapy may at times have unnecessarily delayed and limited the exploration of new chemotherapy drugs and strategies in the treatment of human brain tumors. While antineoplastic drug pharmacology is important in the treatment of all malignant tumors, intrinsic drug cytotoxicity may well be a much more important factor in treatment outcome than is any limitation of drug uptake by the blood-brain barrier.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart DJ: Human central nervous system pharmacology of antineoplastic agents: implications for the treatment of brain tumors. In: Chatel M, Darcel F, Pecker J (eds)Brain Oncology, Biology, Diagnosis, and Therapy, Martinus Nijhoff Publishers, Dordrecht, 1987, pp 387–395

    Google Scholar 

  2. Levin VA: A pharmacologic basis for brain tumor chemotherapy. Sem Oncol 2: 57–61, 1975

    Google Scholar 

  3. Boghdan U: Chemosensitivity of malignant brain tumors: preliminary results. J Neuro-Oncol 1: 149–166, 1983

    Google Scholar 

  4. Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13: 70–82, 1986

    PubMed  Google Scholar 

  5. Ushio Y, Posner J, Shapiro W: Chemotherapy of experimental meningeal carcinomatosis. Cancer Res 37: 1232–1237, 1977

    PubMed  Google Scholar 

  6. Siegal T, Sandbank U, Gabizon A, Siegal T, Mizrachi R, Ben-David E, Catane R: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. J Neuro-Oncol 4: 233–242, 1987

    Google Scholar 

  7. Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain tumors. The ‘blood-brain barrier’ is not a factor. Arch Neurol 34: 523–526, 1977

    PubMed  Google Scholar 

  8. Groothuis DR, Fischer JM, Vick NA, Bigner DD: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65 (Suppl 2): 13–18, 1981

    Google Scholar 

  9. Tator CH: Retention of tritiated methotrexate in a transplantable mouse glioma. Cancer Res 36: 3058–3066, 1976

    PubMed  Google Scholar 

  10. Savaraj N, Lu K, Feun LG, Leavens ME, Stewart DJ, Burgess MA, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-Diaziridinyl 3,6-bis(Carboethoxyamino) 1,4-Benzoquinone, (AZQ NSC 182986). J Neuro-Oncol 1: 15–20, 1983

    Google Scholar 

  11. Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V: Human central nervous system and plasma pharmacology of mitoxantrone. Journal of Neuro-Oncology 6: 75–83, 1988

    PubMed  Google Scholar 

  12. Stewart DJ, Green RM, Hugenholtz H, Richard MT, Dennery J, Montpetit V, Hopkins HS, Thibault M: Human central nervous system pharmacology of tiazofurin. In: Walker MD, Thomas DGT (eds)Biology of Brain Tumor, Martinus Nijhoff Publishers, Boston, 1986, pp 423–427

    Google Scholar 

  13. Stewart DJ, Leavens M, Lu K, Wang YM, Benjamin RS, Ho DH, Yap HY, Loo TL: Central nervous system pharmacology of Baker's antifolate (NSC 139105) in man. J Neuro-Oncology 2: 187–193, 1984

    Google Scholar 

  14. Stewart DJ, Richard M, Hugenholtz H, Dennery J, Belanger R, Gerin-Lajoie J, Montpetit V, Nundy D, Prior J, Hopkins H: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncology 2: 133–139, 1984

    Google Scholar 

  15. Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL: Penetration of N-(phosphoacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Research 40: 3163–3166, 1980

    PubMed  Google Scholar 

  16. Fong KL, Ho DHW, Yap BS, Stewart DJ, Brown NS, Benjamin RS, Freireich EJ, Bodey GP: Clinical pharmacology of IMPY by radio-immunoassay. Cancer Treat Rep 64: 1253–1260, 1980

    PubMed  Google Scholar 

  17. Rosenblum M, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans. Cancer Research 41: 459–462, 1981

    PubMed  Google Scholar 

  18. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982

    PubMed  Google Scholar 

  19. Stewart DJ, Benvenuto J, Leavens M, Smith R, Cabanillas F, Benjamin RS, Loo Ti Li: Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J of Neuro-Oncol 1: 357–364, 1983

    Google Scholar 

  20. Rowe-Jones D: Cytotoxic penetration and concentration in human malignant tumors. Br J Surg 56: 774–778, 1969

    PubMed  Google Scholar 

  21. Straw J, Hart M, Klubes P, Zaharko D, Dedrick R: Distribution of anticancer agents in spontaneous animal tumors I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. J Natl Cancer Inst 52: 1327–1331, 1974

    PubMed  Google Scholar 

  22. Stewart DJ, Mikheal NZ, Nair RC, Kacew S, Montpetit V, Nanji A, Maroun JA, Howard K: Platinum concentrations in human autopsy tumor samples. American Journal of Clinical Oncology (CCT) 11: 152–158, 1988

    Google Scholar 

  23. Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA: Human autopsy tissue concentrations of mitoxantrone. Cancer Treatment Reports 70: 1255–1261, 1986

    PubMed  Google Scholar 

  24. Levin VA, Freeman-Dove W, Landahl HD: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 32: 785–791, 1975

    PubMed  Google Scholar 

  25. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF: Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 67: 697–705, 1987

    PubMed  Google Scholar 

  26. Boucher Y, Baxter LT, Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478–4484, 1990

    PubMed  Google Scholar 

  27. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641–2658, 1988

    PubMed  Google Scholar 

  28. Blasberg RG, Molnar P, Horowitz M, Kornblith P, Pleasants R, Fenstermacher J: Regional blood flow in RT-9 brain tumor. J Neurosurg 58: 863–873, 1983

    PubMed  Google Scholar 

  29. Tachibana H, Meyer JS, Rose JE, Kandula P: Local cerebral blood flow and partition coefficients measured in cerebral astrocytomas of different grades of malignancy. Surg Neurol 21: 125–131, 1984

    PubMed  Google Scholar 

  30. Beaney RP, Brooks DJ, Leenders KL, Thomas DGT, Jones T, Halnan KE: Blood flow and oxygen utilisation in the contralateral cerebral cortex of patients with untreated intracranial tumors as studied by positron emission tomography, with observations on the effect of decompressive surgery. J Neurol Neurosurg Psych 48: 310–319, 1985

    Google Scholar 

  31. Mantyla MJ: Regional blood flow in human tumors. Cancer Res 39: 2304–2306, 1979

    PubMed  Google Scholar 

  32. Reichman HR, Farrell CL, Del Maestro RF: Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J Neurosurg 65: 233–237, 1986

    PubMed  Google Scholar 

  33. Shapiro WR, Hiesiger EM, Cooney GA, Basler GA, Lipschutz LE, Posner J: Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of14C-alpha-aminoisobutyric acid in rat C6 glioma. J Neuro-Oncol 8: 197–204, 1990

    Google Scholar 

  34. Jarden JO, Dhawan V, Poltorak A, Posner JB, Rottenberg DA: Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of82Rb: the effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 18: 636–646, 1985

    PubMed  Google Scholar 

  35. Bruce JN, Criscuolo GR, Merrill MJ, Moquin RR, Blacklock B, Oldfield EH: Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamthasone. J Neurosurg 67: 880–884, 1987

    PubMed  Google Scholar 

  36. Neuwelt EA, Frenkel EP, D'Agostino AN, Carney DN, Minna JD, Barnett PA, McCormick CI: Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 45: 2827–2833 (1985)

    PubMed  Google Scholar 

  37. Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE: Pharmacokinetics of tumor ceil exposure to [14C]methotrexate after intracarotid administration without and with hyperosmolotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. Cancer Res 48: 694–701, 1988

    PubMed  Google Scholar 

  38. Inoue T, Fukui M, Nishio S, Kitamura K, Nagara H: Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J Neurosurg 66: 256–263, 1987

    PubMed  Google Scholar 

  39. Neuwelt EA, Frenkel EP, Rapoport S, Barnett P: Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in dogs. Neurosurg 7: 36–13, 1980

    Google Scholar 

  40. Kassell NF, Baumann KW, Hitchon PW, Gerk MK, Hill TR, Sokoll MD: Neurosurg 9: 283–286, 1981

    Google Scholar 

  41. Villemure JG: personal communication

  42. Hasegawa H, Allen JC, Mehta BM, Shapiro WR, Posner JB: Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 29: 1280–1286, 1979

    PubMed  Google Scholar 

  43. Burke AM, Quest DO, Chien S, Cerri C: The effects of mannitol on blood viscosity. J Neurosurg 55: 550–553, 1981

    PubMed  Google Scholar 

  44. Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS: Penetration of teniposide (VM-26) into human intracerebral tumors: preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin-B or oral glycerol. J Neuro-Oncol 2: 315–324, 1984

    Google Scholar 

  45. Stewart DJ, Grahovac Z, Hugenholtz H, Russell N, Richard M, Benoit B: Combined intraarterial and systemic chemotherapy for intracerebral tumors. Neurosurg 21: 207–214, 1987

    Google Scholar 

  46. Stewart DJ, Grahovac Z, Hugenholtz H, DaSilva V, Richard M, Benoit B, Belanger G, Russell N: Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. J Neuro Oncol 17: 71–79, 1993

    Google Scholar 

  47. Levin VA, Clancy TP, Ausman JI, Rall DP: Uptake and distribution of3H-methotroxate by the murine ependymoblastoma. J Natl Cancer Inst 48: 875–883, 1972

    PubMed  Google Scholar 

  48. Ushio Y, Hayakawa T, Mogami H: Uptake of tritiated methotrexate by mouse brain tumors after intravenous or intrathecal administration. J Neurosurg 40: 706–716, 1974

    PubMed  Google Scholar 

  49. Wodinsky I, Merker PC, Venditti JM: Responsiveness to chemotherapy of mice with L1210 lymphoid leukemia implanted in various anatomic sites. J Natl Cancer Inst 59: 405–408, 1977

    Google Scholar 

  50. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Trader MW: Curative chemotherapy of advanced239Pu-induced osteosarcoma (239PU OS) in mice with 2-β-D-ribofuranosylthiazole-4-carboxamide (T-CAR) and of advanced L1210 with T-CAR plus BCNU. Proc Am Assoc Cancer Res 24: 265, 1983

    Google Scholar 

  51. Chirigos MA, Humphreys SR, Goldin A: Duration of effective levels of three antitumor drugs in mice with leukemia L1210 implanted intracerebrally and subcutaneously. Cancer Chemother Rep 49: 15–19, 1965

    PubMed  Google Scholar 

  52. Freidman HS, Schold SC Jr, Bigner DD: Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Res 46: 224–228, 1986

    PubMed  Google Scholar 

  53. Merker PC, Wodinsky I, Geran RI: Review of selected experimental brain tumor models used in chemotherapy experiments. Cancer Chemother Rep 59: 729–736, 1975

    PubMed  Google Scholar 

  54. Schabel FM Jr, Trader MW, Laster WR Jr, Shaddix SC, Brockman RW: Studies with 2,5-piperazinedione,3,6-bis-(5-chloro-2-piperidyl)-dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU. Cancer Treat Rep 60: 1325–1333, 1976

    PubMed  Google Scholar 

  55. Shapiro WR: The chemotherapy of intracerebral vs subcutaneous murine gliomas. A comparative study of the effect of VM-26. Arch Neurol 30: 222–226, 1974

    PubMed  Google Scholar 

  56. Levin VA, Kabra P: Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58: 787–792, 1974

    PubMed  Google Scholar 

  57. Levin VA, Crafts D, Wilson CB, Kabra P, Hansch C, Boldrey E, Enot J, Neely M: Imidazole Carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II trial of 5-[3,3-bis(2-chloroethy])-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors. Cancer Chemoth Rep 59: 327–331, 1975

    Google Scholar 

  58. The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6: 679–688, 1988

    Google Scholar 

  59. Henderson IC, Harris JR, Kinne DW, Hellman S: Cancer of the breast. Identifying chemotherapy-responsive patients. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds)Cancer: Principles and Practice of Oncology (3rd edition), JB Lippincott Co., Philadelphia, 1989

    Google Scholar 

  60. Sorensen JB, Badsberg JH, Hansen HH: Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications. Br J Cancer 60: 389–393, 1989

    PubMed  Google Scholar 

  61. Donelli MG, Colombo T, Broggini M, Garattini S: Differential distribution of antitumor agents in primary and secondary tumors. Cancer Treat Rep 61: 1319–1324, 1977

    PubMed  Google Scholar 

  62. Broggini M, Colombo T, D'Incalci M: Activity and pharmacokinetics of teniposide in Lewis Lung Carcinomabearing mice. Cancer Treat Rep 67: 555–559, 1983

    PubMed  Google Scholar 

  63. Talmadge J, Fidller I: Metastatic cancer and its biological heterogeneity. Rev Endocrine-Related Cancer 11: 21–27, 1982

    Google Scholar 

  64. Ro J, Ro JY, El-Nagger A, Holmes FA, Close D, Hortobagyi GN: Brain metastasis initial presentation of breast cancer: DNA flow cytometric comparison of two sites. Breast Dis 3: 35–38, 1990

    Google Scholar 

  65. Nicolson G: Metastatic phenotypic diversity and brain metastasis. The Cancer Bulletin 38: 32–38, 1986

    Google Scholar 

  66. Zaffaroni N, Silvestrini R, Sanfilippo O, Daidone MG, De Marco C: Tumor heterogeneity: analysis of the chemosensitivity of different tumor sites of the same patient. Proc 13th Internat Congr Chemother 224: 143–146, 1983

    Google Scholar 

  67. Tanigawa N, Mizuno Y, Hashimura T, Honda K, Satomura K, Hikasa Y, Niwa O, Sugahara T, Yoshida O, Kern DH, Morton DL: Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay. Cancer Res 44: 2309–2312, 1984

    PubMed  Google Scholar 

  68. Schlag P, Schreml W: Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay. Cancer Res 42: 4086–4089, 1982

    PubMed  Google Scholar 

  69. Volpe JJ, Fujimota K, Marasa JCet al.: Relation of C-6 ghal cells in culture to myelin. Biochem J 152: 701–703, 1975

    PubMed  Google Scholar 

  70. Pfeiffer SE, Wechsler W: Biochemically differentiated neoplastic clone of Schwann cells. Proc Natl Acad Sci USA 69: 2885–2889, 1972

    PubMed  Google Scholar 

  71. Horak E, Darling DL, Tarin D: Analysis of organ-specific effects on metastatic tumor formation by studiesin vitro. JNCI 76: 913–922, 1986

    PubMed  Google Scholar 

  72. Mellet LB: Physicochemical considerations and pharmacokinetic behaviour in delivery of drugs to the central nervous system. Cancer Treat Rep 61: 527–531, 1977

    PubMed  Google Scholar 

  73. Yamada K, Hayakawa T, Ushio Y, Arita N, Kato A, Magami H: Regional blood flow and capillary permeability in the ethylnitrosourea-induced rat glioma. J Neurosurg 55: 922–928, 1981

    PubMed  Google Scholar 

  74. Vogel AW: Intratumoral vascular changes with increased size of mammary adenocarcinomas: new method and results. J Nat Cancer Inst 34: 571–578, 1965

    PubMed  Google Scholar 

  75. Blasberg R, Kobayashi T, Patlak C, Shinohara M, Mizoaka M, Rice J, Shapiro W: Regional blood flow, capillary permeability and glucose utilization in two brain tumor models: preliminary observations and pharmacokinetic implications. Cancer Treat Rep 65 (Suppl 2): 3–12, 1981

    Google Scholar 

  76. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643–3653, 1984

    PubMed  Google Scholar 

  77. Aur RJA, Simone J, Hustu HOet al.: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37: 272–281, 1971

    PubMed  Google Scholar 

  78. Aroney RS, Aisner J, Wesley MN, Whitacre MY, Van Echo DA, Slawson RG, Wiernik PH: Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 67: 675–682, 1983

    PubMed  Google Scholar 

  79. Nugent JL, Bunn PA Jr, Matthews MJ, Ihde DC, Cohen MH, Gazdar A, Minna JD: CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 44: 1885–1893, 1979

    PubMed  Google Scholar 

  80. Alexander M, Glatstein EJ, Gordon DJ, Daniels JR: Combined modality treatment for oat cell carcinoma of the lung: a randomized trial. Cancer Treat Rep 61: 1–6, 1977

    PubMed  Google Scholar 

  81. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA: A randomized trial of high-dose (HD) vs low dose (LD) methotrexate (MTX) in the treatment of extensive stage small cell lung cancer. Proc Am Assoc Cancer Res & Am Soc Clin Oncol 22: 505, 1981

    Google Scholar 

  82. Seydel HG, Creech R, Pagano M, Salazar O, Rubin P, Concannon J, Carbone P, Mohuiddin M, Perez C, Matthews M: Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol (CCT) 8: 218–223, 1985

    Google Scholar 

  83. Baglan RJ, Marks JE: Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung. Cancer 47: 41–45, 1981

    PubMed  Google Scholar 

  84. Komaki R: Prophylactic cranial irradiation for small cell carcinoma of the lung. Cancer Treat Symp 2: 35–39, 1985

    Google Scholar 

  85. Maurer LH, Tulloh M, Weiss RBet al.: A randomized combined modality trial in small cell carcinoma of the lung. Cancer 45: 30–39, 1980

    PubMed  Google Scholar 

  86. George SL, Ochs JJ, Mauer AM, Simone JV: The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol 3: 776–781, 1985

    PubMed  Google Scholar 

  87. Muriel FS, Pavlovsky S, Penalver JA, Hidalgo G, Bonesana AC, Eppinger-Helft M, De Macchi GH, Pavlovsky A: Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia. Cancer 34: 418–426, 1974

    PubMed  Google Scholar 

  88. Working Party on Leukemia in Childhood. Treatment of acute lymphoblastic leukemia: effect of ‘prophylactic’ therapy against central nervous system leukemia. Br Med J 2: 381–384, 1973

    Google Scholar 

  89. Nesbit ME, Sather H, Robison LL, Donaldson M, Littman P, Ortega JA, Hammond GD: Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia. A report from Childrens Cancer Study Group. Cancer Res 42: 674–680, 1982

    PubMed  Google Scholar 

  90. Lininger TR, Fleming TR, Eagen RT: Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 48: 2147–2153, 1981

    PubMed  Google Scholar 

  91. Nies BA, Bodey GP, Thomas LB, Brecher G, Freireich EJ: The persistence of extramedullary leukemic infiltrates during bone marrow remission of acute leukemia. Blood 26: 133–141, 1965

    PubMed  Google Scholar 

  92. Simone JV, Holland E, Johnson W: Fatalities during remission of childhood leukemia. Blood 39: 759–770, 1972

    PubMed  Google Scholar 

  93. Mathe G, Schwarzenberg L, Mery AM, Cattan A, Schneider M, Amiel JL, Schlumberger JR, Poisson J, Wajcner G: Extensive histological and cytological survey of patients with acute leukemia in ‘complete remission’. Br Med J 1: 640–642, 1966

    Google Scholar 

  94. Stewart DJ, Keating MJ, McCredie KB, Smith TL, Murphy SG, Bodey GP, Freireich EJ: Natural history of central nervous system acute leukemia in adults. Cancer 47: 184–196, 1981

    PubMed  Google Scholar 

  95. Keating MJ, Smith BS, Gehan EA, McCredie KB, Bodey GP, Spitzer G, Hersh E, Gutterman J, Freireich EJ: Factors related to length of complete remission in adult acute leukemia. Cancer 42: 2017–2029, 1980

    Google Scholar 

  96. West RJ, Graham-Pole J, Hardisty RM, Pike MD: Factors in pathogenesis of central nervous system leukemia. Br Med J 3: 311–314, 1972

    PubMed  Google Scholar 

  97. Baumer JH, Mott MG: Sex and prognosis in childhood acute lymphoblastic leukemia. Lancet ii: 128–129, 1978

    Google Scholar 

  98. George SL, Fernbach DJ, Lu ET: Early deaths in newly diagnosed cases of pediatric acute leukemia. A Southwest Oncology Group Study. Cancer 42: 781–786, 1978

    PubMed  Google Scholar 

  99. Hustu H, Aur RJA, Verzosa MS, Simone JV, Pinkel D: Prevention of central nervous system leukemia by irradiation. Cancer 32: 585–597, 1973

    PubMed  Google Scholar 

  100. Sadeghi A, Payne D, Rubinstein L, Lad T, the Lung Cancer Study Group: Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. Int J Radiation Oncology Biol Phys 15: 89–97, 1988

    Google Scholar 

  101. Paterson AHG, Agarwal M, Lees A, Hanson J, Szafran O: Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49: 651–654, 1982

    PubMed  Google Scholar 

  102. Bonadonna G, Brussamelino E, Valagussa Pet al.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  103. Kolaric K, Roth A, Jelicic I, Matkovic A: A preliminary report on antitumorigenic activity of cisdichlorodiammineplatinum in metastatic brain tumors. Tumori 67: 483–486, 1981

    PubMed  Google Scholar 

  104. Rosner D, Nemoto T, Pickren J, Lane W: Management of brain metastases from breast cancer by combination chemotherapy. J Neuro-Oncol 1: 131–137, 1983

    Google Scholar 

  105. Kantarajian H, Farha PAM, Spitzer G, Murphy WK, Valdivieso M: Systemic combination chemotherapy as primary treatment of brain metastases from lung cancer. Southern Med J 77: 426–430, 1984

    Google Scholar 

  106. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK: Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 7: 916–922, 1989

    PubMed  Google Scholar 

  107. Maroun JA, Stewart DJ, Young V, Belanger R, Crook AF: Effectiveness of VM-26 in non-small cell carcinoma of the lung (NSCCL) with central nervous system (CNS) metastases. Preliminary Results. Proc Am Soc Clin Oncol 1: 140, 1982

    Google Scholar 

  108. Robin E, Bitran JD, Golomb HM, Newman S, Hoffman PC, Desser RK, DeMeester TR: Prognostic factors in patients with non-small cell bronchogenic carcinoma and brain metastases. Cancer 49: 1916–1919, 1982

    PubMed  Google Scholar 

  109. Casimir M, Yap H, Atkinson N, Hortobagyi G, Buzdar A, Fleishman G, Blumenschein G: Prognostic factors for survival of breast cancer (BC) patients (PTS) with central nervous system (CNS) metastases. Proc Am Soc Clin Oncol 2: 105, 1983

    Google Scholar 

  110. Van Hazel GA, Scott M, Eagen RT: The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer 51: 933–937, 1983

    PubMed  Google Scholar 

  111. Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML: Survival with inoperable lung cancer. An integration of prognostic variables based on simple clinical criteria. Cancer 39: 303–313, 1977

    PubMed  Google Scholar 

  112. Goldhirsch A, Gelber RD, Castiglione M for the Ludwig Breast Cancer Study Group: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6: 89–97, 1988

    PubMed  Google Scholar 

  113. Minna JD, Pass H, Glatstein E, Ihde DC: Cancer of the Lung. Prognostic factors. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds)Cancer;Principles and Practice of Oncology (3rd edition) JB Lippincott Co., Philadelphia, 1989, p 632

    Google Scholar 

  114. Shinaki T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Miya T, Okamoto H, Iemura K, Saijo N: A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30: 1–6, 1992

    PubMed  Google Scholar 

  115. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4: 1604–1614, 1986

    PubMed  Google Scholar 

  116. Kennealey GT, Boston B, Mitchell MS, Knobf MK, Bobrow SN, Pezzimenti JF, Lawrence R, Bertino JR: Combination chemotherapy for advanced breast cancer. Two regimens containing Adriamycin. Cancer 42: 27–33, 1978

    PubMed  Google Scholar 

  117. Rosner D, Nemoto T, Pickren J, Lane W: Management of brain metastases from breast cancer by combination chemotherapy. J Neuro-Oncol 1: 131–137, 1983

    Google Scholar 

  118. Greig NH: Chemotherapy of brain metastases: current status. Cancer Treat Rev 11: 157–186, 1984

    PubMed  Google Scholar 

  119. Neuwelt EA, Balaban E, Diehl J, Hill S, Frenkel E: Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurg 12: 662–671, 1983

    Google Scholar 

  120. Stewart DJ, Russell N, Quarrington A, Atack E, Stolbach L: Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of brain. Cancer Treat Rep 67: 287–291, 1983

    PubMed  Google Scholar 

  121. Stewart DJ, Russell N, Dennery J, Richard MT, Atack E, Eapen L, Girard A, Maroun JA, Grahovac Z, Belanger G: Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma. In: Walker MD, Thomas DGT (eds)Biology of Brain Tumor, Martinus Nijhoff Publishers, Boston, 1986, pp 433–436

    Google Scholar 

  122. Kawakami Y, Tabuchi K, Ohnishi R, Asari S, Nishimoto A: Primary central nervous system lymphoma. J Neurosurg 62: 522–527, 1985

    PubMed  Google Scholar 

  123. Socie G, Pipot-Chauffat C, Schlienger M, Legars D, Thurel C, Mikol J, Ifran N, Briere J, Pene F, Gindrey-Vie B, Marin JL, Desablens B, Laugier A: Primary lymphoma of the central nervous system. An unresolved therapeutic problem. Cancer 65: 322–326, 1990

    PubMed  Google Scholar 

  124. Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M: Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65: 1907–1912, 1990

    PubMed  Google Scholar 

  125. Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68: 835–853, 1988

    PubMed  Google Scholar 

  126. De Vita VT Jr, Jaffe ES, Mauch P, Longo DL: Lymphocytic lymphomas. Treatment of localized aggressive lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds)Cancer: principles and Practice of Oncology (3rd edition), JB Lippincott Co., Philadelphia, 1989, pp 1776–1777

    Google Scholar 

  127. Murray K, Kun L, Cox J: Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg 65: 600–607, 1986

    PubMed  Google Scholar 

  128. Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Cancer Treatment Reviews 16: 129–160, 1989

    Google Scholar 

  129. Hirano A, Matsui T: Vascular structures in brain tumors. Hum Pathol 6: 611–621, 1975

    PubMed  Google Scholar 

  130. Long DM: Capillary ultrastructure and the blood brainbarrier in human malignant brain tumors. J Neurosurg 32: 127–144, 1970

    PubMed  Google Scholar 

  131. Coomber BL, Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF: Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of bloodbrain barrier defect. J Neuro-Oncol 5: 299–307, 1987

    Google Scholar 

  132. Fine HA, Dear KBG, Loeffler JS, Black PMcL, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1992

    Google Scholar 

  133. Gutin PH, Wilson CB, Kumar ARV, Boldrey EB, Levin V, Powell M, Enot KJ: Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35: 1398–1404, 1975

    PubMed  Google Scholar 

  134. Eagan RT, Scott M: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1: 38–44, 1983

    PubMed  Google Scholar 

  135. Nir I, Kohn S, Doron Y, Israel O, Front D: Quantitative analysis of tight junctions and the uptake of99mTc in human gliomas. Cancer Investig 4: 519–524, 1986

    Google Scholar 

  136. Long D: Capillary ultrastructure and the blood brain barrier. Human brain tumors. 6th Int Congr Neuropath, Paris 1970, pp 994–996

  137. Bertolone SJ, Baum ES, Krivit W, Hammond GD: A phase II study of cisplatin therapy in recurrent childhood brain tumors. J Neuro-Oncol 7: 5–11, 1989

    Google Scholar 

  138. Rosenstock JG, Packer RJ, Bilaniuk L, Bruce DA, Radcliffe J-L, Savino P: Chiasmatic optic glioma treated with chemotherapy. J Neurosurg 63: 862–866, 1985

    PubMed  Google Scholar 

  139. Mahaley M, Urso M, Whaley R, Silker R, Williams T, Guaspari A: Malignant glioma treatment with interferon. Proc Am Soc Clin Oncol 3: 65, 1984

    Google Scholar 

  140. Sklansky BD, Mann-Kaplan RS, Reynolds AF, Rosenblum ML, Walker MD: 4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460–467, 1974

    PubMed  Google Scholar 

  141. Takeuchi K: A clinical trial of intravenous bleomycin in the treatment of brain tumors. Int J Clin Pharmacol 12: 419–426, 1975

    Google Scholar 

  142. Rosenstock JG, Evans AE, Schut L: Response to vincristine of recurrent brain tumors in children. J Neurosurg 45: 135–140, 1976

    PubMed  Google Scholar 

  143. Newlands ES: VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma. Sem Oncol 12 (Suppl 2): 37–41, 1985

    Google Scholar 

  144. Carey RW, Davis JM, Zervas NT: Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rep 65: 793–795, 1981

    PubMed  Google Scholar 

  145. Allen JC, Bosl G, Walker R: Chemotherapy trials in recurrent primary intracranial germ cell tumors. J Neuro-Oncol 3: 147–152, 1985

    Google Scholar 

  146. Taylor SG IV, Nelson L, Baxter D, Rosenbaum C, Spongo RW, Cunningham TG, Olson KB, Horton J: Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). Cancer 36: 1269–1276, 1975

    PubMed  Google Scholar 

  147. Kida Y, Kobayashi T, Yoshida J, Kato K, Kageyama N: Chemotherapy with cisplatin for AFP-secreting germ-cell tumors of the central nervous system. J Neurosurg 65: 470–475, 1986

    PubMed  Google Scholar 

  148. Stewart DJ, O'Bryan M, Al-Sarraf M, Costanzi JJ, Oishi N: Phase II study of cisplatin in recurrent astrocytomas in adults. J Neuro-Oncol 1: 145–147, 1983

    Google Scholar 

  149. Stewart DJ, Richard M, Hugenholtz HN, Benoit B, Russell N, Dennery J, Peterson E, Maroun JA: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2: 29–34, 1984

    Google Scholar 

  150. Allen JC, Helson J: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749–756, 1981

    PubMed  Google Scholar 

  151. Walker MD, Hilton J: Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep 60: 725–728, 1976

    PubMed  Google Scholar 

  152. Eckhardt S, Csetenyi J, Horvath IP, Kerpel-Fronius S, Szamel I, Institoris L, Szlovik F, Pasztor E, Afra D: Uptake of labelled dianhydrogalactitol into human gliomas and nervous tissue. Cancer Treat Rep 61: 841–847, 1977

    PubMed  Google Scholar 

  153. Ojima Y, Sullivan RD: Pharmacology of methotrexate in the human central nervous system. Surg Gyn Obs 125: 1035–1040, 1967

    Google Scholar 

  154. Hayakawa T, Ushio Y, Morimoto K, Hasegawa H, Mogami H, Horibata K: Uptake of bleomycin by human brain tumors. J Neurol Neurosurg Psych 39: 341–349, 1976

    Google Scholar 

  155. Simon G, Graul EH, Hundeshagen H: Tracer-studien mit radioactiv markiertem cyclophosphamid bei hirntumoren. Acta Neurochir Wien 13: 441–156, 1965

    PubMed  Google Scholar 

  156. Graul EH, Schaumloffel E, Hundeshagen Het al.: Metabolism of radioactive cyclophosphamide: animal tests and clinical studies. Cancer 20: 896–899, 1967

    PubMed  Google Scholar 

  157. Haranda K, Kiya K, Uozumi T: Pharmacokinetics of a new water-soluble nitrosourea derivative (ACNU) in human gliomas. Surg Neurol 15: 410–414, 1980

    Google Scholar 

  158. Sziklai I, Afra D, Ordogh M, Institoris L, Kerpel-Fronius S, Szabo E: The distribution of bromine content of dibromodulcitol in the central nervous system of patients with malignant gliomas. Eur J Cancer 26: 79–82, 1990

    PubMed  Google Scholar 

  159. Savaraj N, Feun LG, Lu K, Leavens M, Moser R, Fields WS: Central nervous system (CNS) penetration of homoharringtonine (HHT). J Neuro-Oncol 5: 77–81, 1987

    Google Scholar 

  160. Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM: Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641–645, 1991

    PubMed  Google Scholar 

  161. Stewart DJ, Benjamin RS, Luna M, Scifert WE, Loo TL: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother & Pharm 10: 51–54, 1982

    Google Scholar 

  162. Gregg RW, Stewart DJ, Molepo JM, Montpetit VJA, Mikhael NZ, Redmond D, Gadia M: Cisplatin neurotoxicity — the relationship between dosage, time, platinum concentration in neurological tissues and morphological evidence of toxicity. J Clin Oncol 10: 795–803, 1992

    PubMed  Google Scholar 

  163. Stewart DJ, Grewaal D, Green R, Goel R, Mikhael N, Montpetit VAJ, Redmond D, Earhart R: Human autopsy tissue distribution of menogaril and its metabolites. Cancer Chemotherapy and Pharmacology 32: 373–378, 1993

    PubMed  Google Scholar 

  164. Stewart DJ, Lu K, Benjamin RS, Leavens M, Luna M, Yap HY, Loo TL: Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neuro-Oncol 1: 139–144, 1983

    Google Scholar 

  165. Stewart DJ, Grewaal D, Redmond D, Mikhael N, Montpetit V, Goel R, Green R: Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. Cancer Chemotherapy and Pharmacology 32: 368–372, 1993

    PubMed  Google Scholar 

  166. Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Benjamin RS, Keating MJ, Loo TL: Human tissue distribution of 4′-(9-Acridinylamino)-methanesulfon-m-aniside (NSC 14159, AMSA). Cancer Chemotherapy and Pharmacology 12: 116–119, 1984

    PubMed  Google Scholar 

  167. Stewart DJ, Rosenblum M, Luna M, Loo TL: Disposition of methylglyoxyl bis (Guanylhydrazone) (MGBG, NSC-32946) in man. Cancer Chemotherapy and Pharmacol 7: 31–35, 1981

    Google Scholar 

  168. Benvenuto JA, Hall SW, Farquhar D, Stewart DJ, Benjamin RS, Loo TL: Clinical pharmacology of 3-deazauridine. Cancer Research 39: 349–352, 1979

    PubMed  Google Scholar 

  169. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KD, Burgess MA, Loo TL: Penetration of 3-deazauridine into human brain, intracerebral tumor and cerebrospinal fluid. Cancer Research 39: 4119–1122, 1979

    PubMed  Google Scholar 

  170. Seifert WE Jr, Stewart DJ, Dolupski JB, Benjamin RS, Caprioli RM: Energy dispersive x-ray fluorescence determination of platinum in plasma, urine, and CSF of patients administered cis-Dichlorodiammineplatinum (II). Cancer Chemotherapy and Pharmacology 11: 120–123, 1983

    PubMed  Google Scholar 

  171. Zhengang G, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, Loo TL: Tumor penetration of AMSA in man. Cancer Investigation 1: 475–478, 1983

    PubMed  Google Scholar 

  172. Loo TL, Friedman E, Moore EC, Valdivieso M, Marti JR, Stewart DJ: The pharmacologic disposition of N-(phosphonacetyl)-L-aspartate in humans. Cancer Research 40: 86–90, 1980

    PubMed  Google Scholar 

  173. Hall SW, Yeung K, Benjamin RS, Stewart DJ, Valdivieso M, Bedikian AY, Loo TL: Kinetics of gallium nitrate: a new anticancer agent. Clinical Pharmacology and Therapeutics 25: 82–87, 1979

    PubMed  Google Scholar 

  174. Stewart DJ, Grewaal D, Green RM, Mikhael N, Montpetit V, Redmond D; Adriamycin concentrations in human autopsy intracerebral and extracerebral tumors. J Neuro-Oncol 7 (Suppl): S27, 1989

    Google Scholar 

  175. Stewart DJ, Molepo JM, Green R, Hugenholtz H, Lamothe A, Montpetit VJA, Redmond MD, Mikhael NZ: Factors affecting tumor cisplatin levels. Proc Am Assoc Cancer Res 31: 180, 1990

    Google Scholar 

  176. Stewart DJ, Molepo M, Eapen L, Montpetit V, Goel R, Wong P, Popovic P, Taylor K, Raaphorst GP: Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Internat J Radiation Biol Phys. 28: 531–542, 1994

    Google Scholar 

  177. Montpetit VJA, Stewart D, Molepo JM, Mikhael N, Dancea S, Keaney MA: Cisplatinum neurotoxicity in ferrets: correlation of platinum concentration in neural tissues with sensory neuropathy. J Neuropathol Exp Neurol 48: 371, 1989

    Google Scholar 

  178. DeGregorio M, Wilbur B, King O, Wallenberg J, Prewitt S, Phillips J, Wilbur J: Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration. Cancer Treat Rep 70: 1437–1438, 1986

    PubMed  Google Scholar 

  179. DeGregorio MW, King OY, Holleran WM, Wilbur BJ, Cadman EC, Deisseroth AB, Wilbur JR: Ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma. Cancer Treat Rep 69: 1441–1442, 1985

    PubMed  Google Scholar 

  180. Bonnern EM, Litterst CL, Smith FP: Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep 66: 1661–1663, 1982

    PubMed  Google Scholar 

  181. Popovic P, Wong PTT, Goel R, Evans WK, Howell SB, Auersperg N, Stewart DJ: Pressure-tuning infrared spectroscopy of cisplatin sensitive vs resistant ovarian cancer cells. Proc Amer Assoc Cancer Res 33: 464, 1992

    Google Scholar 

  182. Popovic P, Teicher B, Wong PTT, Goel R, Stewart DJ: Pressure tuning infrared spectroscopy of EMT-6 tumor and its cyclophosphamide- and cisplatin-resistant variants. Proc AACR 34: 405, 1993

    Google Scholar 

  183. Vrignaud P, Montaudon D, Londos-Gagliardi D, Robert J: Fatty acid composition transport and metabolism in doxorubicin-sensitive and -resistant rat glioblastoma cells. Cancer Res 46: 3258–3261, 1986

    PubMed  Google Scholar 

  184. Taylor KD, Goel R, Stewart DJ, Wong PTT: Pressure tuning spectroscopic of cisplatin induced changes in a phosphatidylcholine model membrane. Proc AACR 34: 401, 1993

    Google Scholar 

  185. Taylor KD, Goel R, Stewart DJ, Wong PTT: Pressure tuning infrared spectroscopic study of cisplatin induced changes in phosphatidylserine model membrane. Proc Amer Assoc Cancer Res 33: 448, 1992

    Google Scholar 

  186. Popovic P, Wong PTT, Kates M, Grewaal D, Goel R, Molepo JM, Stewart DJ: Membrane fluidity and lipids in cisplatin resistant cells with low cisplatin uptake. Proc Am Assoc Cancer Res 35: 440, 1994

    Google Scholar 

  187. Van Blitterswijk WJ, van der Meer BW, Hilkman H: Quantitative contributions of cholesterol and the individual classes of phospholipids and their degree of fatty acyl (un) saturation to membrane fluidity measured by fluorescence polarization. Biochem 26: 1746–1756, 1987

    Google Scholar 

  188. Andrews PA, Velury S, Mann SC, Howell SB: cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Research 48: 68–73, 1988

    PubMed  Google Scholar 

  189. Stewart DJ, Grewaal D, Popovic P, Molepo JM, Shirazi SFH, Goel R: Alteration of cisplatin uptake into lung cancer cell lines. Proc Am Assoc Cancer Res 35: 440, 1994

    Google Scholar 

  190. Lathrop BK, Biltonen RL: Calcium and magnesium dependence of phospholipase A2-catalyzed hydrolysis of phosphatidylcholine small unilamellar vesicles. J Biol Chem 267 (30): 21425–21431, 1992

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ontario Cancer Treatment and Research Foundation, The University of Ottawa Faculty of Medicine, Canada

    David J. Stewart

Authors
  1. David J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, D.J. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 20, 121–139 (1994). https://doi.org/10.1007/BF01052723

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01052723

Key words

Search

Navigation